Bairagi, Keshab M. published the artcileAntidiabetic Activity of Dihydropyrimidine Scaffolds and Structural Insight by Single Crystal X-ray Studies, HPLC of Formula: 30414-53-0, the publication is Medicinal Chemistry (Sharjah, United Arab Emirates) (2020), 16(7), 996-1003, database is CAplus and MEDLINE.
This research project is designed to identify the anti-diabetic effects of the newly synthesized compounds to conclude the perspective of consuming one or more of these new synthetic compounds for diabetes management. A series of dihydropyrimidine (DHPM) derivative bearing electron releasing and electron-withdrawing substituent′s on Ph ring (a-j) were synthesized and screened for antihyperglycemic(anti-diabetic) activity on streptozotocin (STZ) induced diabetic rat model. The newly synthesized compounds were characterized by using FT-IR, m.p., 1H and 13C NMR anal. The crystal structure and supramol. features were analyzed through single-crystal X-ray study. Anti-diabetic activity testing of newly prepared DHPM scaffolds was mainly based on their relative substituent on the Ph ring along with urea and thiourea. Among the synthesized DHPM scaffold, the test compound c having chlorine group on Ph ring at the ortho position to the hydropyrimidine ring with urea and Me acetoacetate derivative shows moderate lowering of glucose level. However, the title compounds Me 4-(4-hydroxy-3-methoxyphenyl)- 6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate(g) and Et 4-(3-ethoxy-4- hydroxyphenyl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate(h) having methoxy and ethoxy substituents on Ph ring show significant hypoglycemic activity compared to the remaining compounds from the Scheme 1. The exptl. rat models for the study were divided into 13 groups (n = 10); group 1 animals were treated with 0.5% CMC (0.5mL) (vehicle); group 2 were considered the streptozotocin (STZ)/nicotinamide diabetic control group (DC) and untreated, group 3 diabetic animals were administered with gliclazide 50 mg/kg and act as a reference drug group. The remaining groups of the diabetic animals were administered with the newly synthesized dihydropyrimidine compounds in a single dose of 50 mg/kg orally using the oral gavage, daily for 7 days continuously. The blood glucose level was measured before and 72 h after nicotinamide-STZ injection, for confirmation of hyperglycemia and type 2 diabetes development. Blood glucose levels were significantly (p<0.05) reduced after treatment with these derivatives The mean percentage reduction for gliclazide was 50%, while that of synthesized compounds were approx. 36%. Our result suggests that the synthesized new DHPM derivative containing alkoxy group on the Ph ring shows a significant lowering of glucose level compared to other derivatives
Medicinal Chemistry (Sharjah, United Arab Emirates) published new progress about 30414-53-0. 30414-53-0 belongs to esters-buliding-blocks, auxiliary class Aliphatic hydrocarbon chain,Ketone,Ester, name is Methyl 3-oxovalerate, and the molecular formula is C6H10O3, HPLC of Formula: 30414-53-0.
Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics